PDCD1 and neoplasm: In preclinical studies, the combination of nitrofurantoin (a pharmacological agent restoring EHF expression) with anti-PD-1 antibody and gemcitabine (GEM) markedly suppressed tumor growth, demonstrating significant translational therapeutic potential (113).